Schmeiser, Olsen & Watts, LLP
Antibody-drug conjugates based on gold compounds
Antibody-drug-conjugates (ADC) are provided having a structure of: wherein L is PR3 ligand. The ADC has n drug moieties bound to the Trastuzumab antibody such that the ADC has a drug-to-antibody ratio (DAR) between 2 and 4 and the drug moieties are bound to the Trastuzumab antibody through cysteine (S) or lystine (Lys) residues. The disclosed ADCs are particularly useful in treating breast cancer. 
Memorial Sloan Kettering Cancer Center Research Foundation of the City University of New York
A A A A A A A
A61K A61K A61K A61P A61K A61K A61K
inventional inventional inventional inventional inventional inventional inventional
Sophie Maria Natalia Jason
Poty Contel Curado Lewis